Jefferies Reiterates Compass Pathways Buy After COMP360 Results
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
compass-pathwayspsychedelic-therapymental-health-stocksclinical-trials
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Jefferies reiterated a Buy rating and a $24 price target on COMPASS Pathways (CMPS) stock on July 7, 2026, following the publication of phase 2b trial results for its lead investigational therapy, COMP360 psilocybin. The analyst action underscores institutional confidence in the data as the company progresses towards a pivotal phase 3 program. The trial reported a statistically significant 36% remission rate for treatment-resistant depression (TRD) patients receiving a single 25mg dose with psychological support, versus 17.7% for the active control group.
The last major efficacy readout in the psychedelic-assisted therapy sector was MindMed's phase 2b trial for Generalized Anxiety Disorder in November 2025, which showed a 14.5-point improvement on the Hamilton Anxiety Scale. The current macro backdrop for biotech is characterized by elevated capital costs, with the 10-year Treasury yield at 4.21%, pressuring speculative pre-revenue companies. What triggered the Jefferies reiteration now was the peer-reviewed publication of COMP360's full dataset in a major medical journal, providing granular safety and efficacy details ahead of an End-of-Phase 2 meeting with the FDA. This final, vetted data de-risks the regulatory pathway and provides a clearer template for the design of the upcoming phase 3 trials, a critical step for securing partnership interest.
The phase 2b trial enrolled 233 patients with treatment-resistant depression. The primary endpoint was change in the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 3. The 25mg dose cohort showed a -6.6 point difference versus the 1mg control, achieving a p-value of 0.002. The key secondary endpoint of remission at week 12 showed a 36.0% rate for the 25mg group versus 17.7% for the 1mg control. The safety profile was consistent with prior studies, with 84% of treatment-emergent adverse events reported as mild or moderate. COMPASS Pathways ended Q1 2026 with approximately $263 million in cash and equivalents, funding operations into 2028. The analyst's $24 price target implies a 65% upside from CMPS's closing price of $14.52 on July 6. The stock's year-to-date performance of +22% contrasts with the SPDR S&P Biotech ETF (XBI), which is down -3% over the same period.
| Metric | 25mg COMP360 Group | 1mg Control Group |
|---|---|---|
| MADRS Reduction at Week 3 | -12.0 points | -5.4 points |
| Remission Rate at Week 12 | 36.0% | 17.7% |
The clear efficacy signal is a net positive for the entire psychedelic-assisted therapy sector, likely drawing incremental institutional capital into the space. Direct beneficiaries include companies with late-stage assets, such as Cybin (CYBN), which is conducting a phase 3 trial for Major Depressive Disorder, and Atai Life Sciences (ATAI), a major shareholder in COMPASS. Contract research organizations specializing in central nervous system trials, like Medpace (MEDP), also stand to gain from increased trial activity. A key limitation is the therapy's commercial model; the requirement for medically-supervised administration sessions will create reimbursement challenges and limit patient throughput. Current positioning shows hedge funds and specialist healthcare funds accumulating long positions in CMPS, while generalist investors remain on the sidelines awaiting phase 3 initiation. Short interest remains elevated at approximately 18% of the float, reflecting skepticism about ultimate commercialization.
The immediate catalyst is the scheduled End-of-Phase 2 meeting with the FDA in Q4 2026, which will finalize the phase 3 trial design. The next major data readout will be COMPASS's phase 3 trial in Post-Traumatic Stress Disorder, with topline results expected in H2 2027. Investors should monitor the company's cash burn rate against its $263 million war chest; a figure exceeding $40 million per quarter may pressure the stock. Key technical levels for CMPS stock are the 50-day moving average at $13.85 as near-term support and the 200-day moving average at $16.20 as resistance. A break above $17 on volume would signal a potential re-rating, while a close below $12.50 could indicate a failed breakout. Further analysis on biotech valuation models is available at https://fazen.markets/en.
Existing pharmacotherapies for treatment-resistant depression, like Johnson & Johnson's Spravato (esketamine), report remission rates around 25-30% in clinical settings. COMP360's 36% remission rate in a rigorously controlled trial suggests a potentially superior efficacy profile for a subset of patients. However, COMP360 is a single-dose therapy with psychological support, while Spravato is typically administered twice weekly, making direct comparisons complex. The cost and logistical burden of each modality will be a decisive factor for payers.
The primary regulatory hurdle is the FDA's requirement for a Risk Evaluation and Mitigation Strategy (REMS) due to the controlled substance status of psilocybin. A REMS program would mandate strict administration protocols, certified treatment centers, and patient monitoring. The FDA must be convinced that this framework sufficiently mitigates potential for misuse and ensures patient safety outside a clinical trial setting. This process adds significant time and cost to the path to market.
The advancement of a novel mechanism like psilocybin exerts long-term disruptive pressure on traditional pharmaceutical approaches to mental health. Companies with large revenue bases in conventional antidepressants, such as AbbVie (with its acquisition of Cerevel) and Bristol Myers Squibb, may face incremental market share risk over a decade-long horizon. Conversely, providers of specialized psychiatric care and therapy integration services could see demand growth. More on sector displacement is available at https://fazen.markets/en.
Jefferies' reaffirmed Buy rating signals that COMP360's phase 2b data provides a sufficient efficacy benchmark to justify investment ahead of pivotal phase 3 trials.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.